Inovio's (INO) Less-Talked-About HIV Program Progresses; Stifel Affirms at 'Buy'
Tweet Send to a Friend
Stifel affirms Inovio (Nasdaq: INO) at Buy with a price target of $13 after the company announced that its novel ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE